: Influenza is an acute respiratory illness caused by the influenza A, B, and C viruses. It can occur in local outbreaks or seasonal epidemics, with possibility to spread worldwide in a pandemic when a novel strain with significant antigenic differences emerges. During the past years, several new drugs have become available, with different accessibility related to specific countries' approval. We have conducted a review of literature, analyzing the most recent data on efficacy and safety of drugs currently available to treat influenza, with a particular attention toward special populations. Efficacy and safety profile of neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and recently approved cap-dependent endonuclease inhibitor baloxavir marboxil are reported in literature, but still little information is available about special populations such as critically ill patients and patients with a history of chronic respiratory disease. Moreover, the emergence of strains with reduced or no susceptibility to current drugs is a matter of concern, suggesting the need of constant monitoring of viral variants.

Antiviral Treatments for Influenza / E. Palomba, V. Castelli, G. Renisi, A. Bandera, A. Lombardi, A. Gori. - In: SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE. - ISSN 1069-3424. - 42:6(2021 Dec 16), pp. 859-872. [10.1055/s-0041-1733830]

Antiviral Treatments for Influenza

E. Palomba
Primo
;
V. Castelli
Secondo
;
A. Bandera;A. Lombardi
Penultimo
;
A. Gori
Ultimo
2021

Abstract

: Influenza is an acute respiratory illness caused by the influenza A, B, and C viruses. It can occur in local outbreaks or seasonal epidemics, with possibility to spread worldwide in a pandemic when a novel strain with significant antigenic differences emerges. During the past years, several new drugs have become available, with different accessibility related to specific countries' approval. We have conducted a review of literature, analyzing the most recent data on efficacy and safety of drugs currently available to treat influenza, with a particular attention toward special populations. Efficacy and safety profile of neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and recently approved cap-dependent endonuclease inhibitor baloxavir marboxil are reported in literature, but still little information is available about special populations such as critically ill patients and patients with a history of chronic respiratory disease. Moreover, the emergence of strains with reduced or no susceptibility to current drugs is a matter of concern, suggesting the need of constant monitoring of viral variants.
influenza; antiviral treatments; neuraminidase inhibitors; influenza cap-dependent endonuclease;
Settore MED/17 - Malattie Infettive
16-dic-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
SRCCM_210613.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 440.73 kB
Formato Adobe PDF
440.73 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/891704
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact